dpp4 and glp 1 together DPP-4 inhibitors GLP-1RAs: cardiovascular safety and benefits | Military Medical Research Frontiers | Clinical Use of

In summary, ferroptotic factors are potential targets for therapeutic intervention to alleviate different kidney diseases, and targeting them may lead to new treatments for patients with kidney diseases

Cause irreversible denaturation of the cyclic peptide structure

Soule et al

Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose

Clin Exp Rheumatol (2021) 39(1):112